Latest Biotechnology, Pharmaceutical and Healthcare News from PharmaTimes

09:35 EDT 15th August 2018 | BioPortfolio

Here are the most relevant search results for "PharmaTimes" found in our extensive news archives from over 250 global news sources.

More Information about PharmaTimes on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about PharmaTimes for you to read. Along with our medical data and news we also list PharmaTimes Clinical Trials, which are updated daily. BioPortfolio also has a large database of PharmaTimes Companies for you to search.

Showing News Articles 1–25 of 1,000+ from PharmaTimes

Wednesday 15th August 2018

Lancet publishes PhIII data on Kyowa Hakko’s Poteligeo

The Lancet has published data from Kyowa Hakko Kirin Co’s successful Phase III trial of immunotherapy Poteligeo underpinning its recent approval in the US to treat in patients with cutaneous T-cell lymphoma (CTCL).

Blood test could detect kidney cancer up to five years earlier

Scientists have discovered a marker in the blood that could predict the risk of developing kidney cancer.

ViiV, Janssen’s two-drug HIV regimen hits PhIII targets

ViiV Healthcare and Janssen have unveiled positive headline data from a late-stage trial of their injectable two-drug regimen for the treatment of HIV.

All London GP practices now using electronic prescriptions

GP practices across London have successfully made the switch to using the Electronic Prescription Service (EPS), saving hours of time and money, NHS Digital says.

Emergency hospital visits more likely for deprived bowel cancer patients

Emergency hospital visits are more common among patients with bowel cancer living in the most deprived areas of the country than for those living in affluent regions, research funded by Cancer Research UK has found.

Tuesday 14th August 2018

Four new medicines cleared for use on NHS Scotland

The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema.

Xolair deemed ‘breakthrough’ therapy for food allergies

Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens.

Draft guidelines reject NHS funding for Biogen’s Spinraza

The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time.

Motif Bio’s antibiotic granted US priority review

US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Orchard raises $150m to advance gene therapies

UK-American biotech Orchard Therapeutics has raised $150 million to fuel development of its gene therapy pipeline.

Monday 13th August 2018

Bowel cancer screening to start 10 years earlier

Bowel cancer screening in England and Wales is to start a decade earlier in a drive to pick up more cases of the disease at an earlier stage, the government has confirmed.

Amicus’ Galafold wins US approval

Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease.

Astellas buys UK group Quethera

Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma.

Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis

The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis.

Friday 10th August 2018

Pharma lacks engagement with mental health groups: report

Janssen ranks first in new survey of pharma's reputation among mental health patient groups

Medical & Scientific Advisors to get the recognition they deserve

PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events.

New charity award to focus on real challenges

The PharmaTimes Communications Team of the Year competition is the only pharma industry awards that tests the competencies and potential of communications agency teams, benchmarking talent agency side. This year sees the introduction of a new 'Charity Challenge', which in partnership with Beating Bowel Cancer and Bowel Cancer UK, will focus on a real life scenario for the first time.

Embracing the importance of cross functional working

Director of policy and communications at MSD and executive steering group member Harry Brady looks at how the PharmaTimes Marketer and Communications Team of the Year competitions have evolved to embrace the importance of cross-functional working and the value of great healthcare communications in the marketing mix.

Artios Pharma raises £65m to develop DDR therapies

Oversubscribed financing includes investment from Pfizer and Novartis

Merck profits decline but new drugs maintain sales growth

Strong performances for Mavenclad and Bavencio

Thursday 9th August 2018

Perrigo plans to separate prescription drugs business

Chairman says consumer and Rx platforms are "navigating divergent industry dynamics"

Ligand to buy UK biotech Vernaliss for $43 million

San Diego-based Ligand would acquire programmes in respiratory, oncology and CNS

NICE changes its mind on Pfizer’s Besponsa

Following an appeal the drug will now be available to treat ALL

Wednesday 8th August 2018

Takeda partners with new biotech Ambys in liver disease

Takeda has committed $100 million, including the participation in the Series A financing, to Ambys

Quanticate names David Hukin senior director of Pharmacovigilance

Quick Search


News Quicklinks